lung-cancer

Documents about lung-cancer

• Current Status of Immunotherapy in Resectable Lung Cancer.#433898NCBI PubMed Central
• Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry#254454IRIS
• Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors#195313ClinicalTrials.gov
• Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung Cancer#429744ClinicalTrials.gov
• Mapping metabolic reprogramming in lung and breast cancer through integrative bioinformatics#258679PLOS
• Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin#311123ClinicalTrials.gov
• Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors#245375ClinicalTrials.gov
• Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer#174868ClinicalTrials.gov
• Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors#195413ClinicalTrials.gov
• The lived experiences of individuals with early stage non-small cell lung cancer following lung surgery: A rapid ethnographic approach.#195978NCBI PubMed Central
• Liquid Biopsy Based NGS in Newly Diagnosed NSCLC#226272ClinicalTrials.gov
• The Third Joint Meeting on Lung Cancer of the FHU OncoAge (University Côte d’Azur, Nice, France) and the University of Texas MD Anderson Cancer Center (Houston, TX, USA). Understanding New Therapeutic Options and Promising Predictive Biomarkers for Lung Cancer Patients#215406HAL (France)
• Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy#184834ClinicalTrials.gov
• Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling - a Prospective Canadian Study#363600ClinicalTrials.gov
• Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes#366577ClinicalTrials.gov
• SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II#394760ClinicalTrials.gov
• Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy#432899ClinicalTrials.gov
• Detection of Tumor Recurrence via Circulating Tumor DNA Profiling in Patients with Localized Lung Cancer: Clinical Considerations and Challenges#178213HAL (France)
• Deciphering the Impact of HER2 Alterations on Non-Small-Cell Lung Cancer: From Biological Mechanisms to Therapeutic Approaches#215401HAL (France)
• The significance of co-mutations in EGFR-mutated non-small cell lung cancer: Optimizing the efficacy of targeted therapies?#215411HAL (France)
• Critical requirement of SOS1 for tumor development and microenvironment modulation in KRASG12D-driven lung adenocarcinoma#294496Gestión del Repositorio Documental de la Universidad de Salamanca
• Organ-Specific Differences in Immunotherapy Response Among Metastatic Cancer Patients#287556ClinicalTrials.gov
• Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma#290951ClinicalTrials.gov
• Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors#383548ClinicalTrials.gov
• Table 1_Integrative single-nucleus transcriptomic analysis identifies UBE2C+ proliferative tumor cells and immune-stromal regulatory crosstalk in small cell lung cancer.docx#424573Figshare
• A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies#180380ClinicalTrials.gov
• Serum biomarker profiles as diagnostic tools in lung cancer#129213PMC Full-Text (OAI)
• ThermoTargetMiner Charts the Proteome-Wide Target Landscape of Lung Cancer Therapeutics#133186bioRxiv / medRxiv
• Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment#160343ClinicalTrials.gov
• Drug Concentration Monitoring of Pembrolizumab in Non-Small Cell Lung Cancer Patients#160351ClinicalTrials.gov
• Mediastinal staging: when and how?#254391IRIS
• Ambient air pollution as a risk factor for lung cancer#285701Redalyc
• L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC#394764ClinicalTrials.gov
• Radiotherapy to All Residual Lesions After Chemoimmunotherapy#405152ClinicalTrials.gov
• The Lung Cancer Prediction Model “Stress Test”#428256PubMed Central
• Examining the role of extrachromosomal DNA in lung cancer.#439250NCBI PubMed Central
• Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab#442078ClinicalTrials.gov
• Integrating Lung Tissue-based Transcriptome-Wide Association Study with Single-cell RNA-sequencing Uncovers Susceptibility Genes and Cell Types Underlying Lung Cancer Risk#67966bioRxiv / medRxiv
• Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)#123472ClinicalTrials.gov
• Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial#28299ClinicalTrials.gov
• Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group#218144HAL (France)
• The Association Between Lung Cancer Stigma and Race: A Descriptive Correlational Study#228603Scholar Commons
• Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study#257451HAL (France)
• Antibody-Drug Conjugates Beyond HER2 in Non-Small Cell Lung Cancer (NSCLC): Mechanisms, Emerging Targets, and Future Directions#289054ODU Digital Commons
• A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression#311115ClinicalTrials.gov
• Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study#368427OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC#140986ClinicalTrials.gov
• Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics#146467ClinicalTrials.gov
• Transcription Factor Subtype Governs Response and Resistance to DLL3-Directed T-Cell Engagement in Small Cell Lung Cancer#160425bioRxiv / medRxiv
• Construction and Validation of a Risk Prediction Model for Cancer-Related Cognitive Impairment in Lung Cancer Patients.#437292NCBI PubMed Central